Medicare Obesity Coverage Starts Wednesday – What That Means for NVO and LLY

Starting July 1, Medicare beneficiaries with Part D can get obesity drugs like Wegovy and Zepbound through a new program for a $50 monthly copay. That is the headline. The stock reaction so far has been muted, and the reason may be that 82% of seniors – including 79% of Republicans and 84% of Democrats – have no idea the coverage exists, according to a June survey by the Obesity Care Advocacy Network.

Simple read: more eligible patients means more scripts for Novo Nordisk (NVO) and Eli Lilly (LLY). Over time, that should lift revenue. The Bridge program runs through 2027, and CMS says beneficiaries are most likely to act when a benefit is live. That logic suggests a gradual uptake curve rather than a step-function jump in July.

Better market read: the ramp may be slower than the Street expects. Enrollment is not automatic. Patients need a prescription and prior authorization from CMS. Private Part D plans are not handling the marketing – CMS administers the program directly. That removes the usual channel through which insurers nudge their members toward covered drugs. Kenneth Thorpe, a health policy professor at Emory, told CNBC that “getting the word out” is going to be one of the largest challenges.

Leerink analyst David Risinger said he was surprised Novo and Lilly have not run more advertising aimed at seniors. Novo spent nearly $500 million on U.S. ads for Wegovy and Ozempic in the first nine months of 2025. That spend has focused on TV and subway campaigns. So far no linear TV ads are promoting the Bridge program, Novo’s U.S. operations chief Jamey Millar acknowledged. Millar expects awareness to come through pharmacists and providers, not direct-to-consumer marketing.

Lilly’s president of U.S. operations, Ilya Yuffa, said the company is deliberately building provider awareness first – the same playbook used for the recent Foundayo launch – to avoid friction when patients show up with questions. He said broader consumer marketing for Bridge-eligible Zepbound will come later.

For traders, the slow awareness ramp means near-term script growth from Medicare may underwhelm. The first month of prior authorization data, which CMS typically reports with a lag, will be the read-through. If approvals are low, the market may push revenue expectations for 2025 back into 2026. If they accelerate in August and September, the patient funnel is working.

The program is broad but excludes anyone already getting a GLP-1 for a covered use like diabetes or sleep apnea. That caps the upside from switching. The real new volume comes from seniors with obesity alone who have been paying out of pocket or avoiding treatment.

The Bridge program is not a permanent Medicare Part D benefit. It is a demonstration that runs until 2027. That puts a timebound ceiling on the revenue tailwind unless Congress expands coverage later. CMS has not committed to an extension beyond 2027.

The key number to watch is not the July 1 start date but the rate of prior authorization approvals in the first six weeks. If pharmacies and physicians are prepared, the ramp will be visible by August earnings calls for both companies. If not, the stock will trade on pipeline and non-Medicare demand until the awareness gap closes.